Somewhat surprisingly #Vosevi approved only for DAA non responders

#Vosevi for #HCV treatment contraindicated with rifampin and decompensated cirrhosis. Not recommended with cyclosporine

No additional benefit of #vosevi over #epclusa among #HCV GT1b,2,4,5,6 who failed #sovaldi so remains a rare unmet need

@EASLnews @EASLedu PGC: Prof. Hezode highlights one of the last frontier of #HCV therapy: the compensated, cirrhotic GT3, rx experienced patient. #Vosevi 12 weeks or #mavyret 16 weeks increases the cure rate to high 90% #ilc2018

No...that money goes into research, materials needed, paying their workers, equipment, storage, etc. They don't pocket that money. They get more money from medicine for HCV infections than vaccines. Look at the cost for just Vosevi.

Mavyret and Vosevi--two new combinations for chronic HCV infection